# Cellular Immune Augmentation in Colon and Rectal Cancer

> **NCT00257322** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 20 (actual)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT00257322
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257322, "Cellular Immune Augmentation in Colon and Rectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00257322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*